Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Pirkko Santavuori is active.

Publication


Featured researches published by Pirkko Santavuori.


Nature Genetics | 1998

CLN5 , a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis

Minna Savukoski; Tuomas Klockars; Ville Holmberg; Pirkko Santavuori; Eric S. Lander; Leena Peltonen

The neuronal ceroid lipofuscinoses (NCLs) represent a group of common recessive inherited neurodegenerative disorders of childhood, with an incidence of 1:12,500 live births. They are characterized by accumulation of autofluorescent lipopigments in various tissues. Several forms of NCLs have been identified, based on age at onset, progression of disease, neurophysiological and histopathological findings and separate genetic loci. All types of NCL cause progressive visual and mental decline, motor disturbance, epilepsy and behavioral changes, and lead to premature death. One of the subtypes, Finnish variant late infantile neuronal ceroid lipofuscinosis (vLINCL; MIM256731) affects children at 4–7 years of age. The first symptom is motor clumsiness, followed by progressive visual failure, mental and motor deterioration and later by myoclonia and seizures. We have previously reported linkage for vLINCL on chromosome 13 (ref. 5) and constructed a long-range physical map over the region. Here, we report the positional cloning of a novel gene, CLN5, underlying this severe neurological disorder. The gene encodes a putative transmembrane protein which shows no homology to previously reported proteins. Sequence analysis of DNA samples from patients with three different haplotypes revealed three mutations; one deletion, one nonsense and one missense mutation, suggesting that mutations in this gene are responsible for vLINCL.


Neurology | 1997

Ibuprofen or acetaminophen for the acute treatment of migraine in children : A double-blind, randomized, placebo-controlled, crossover study

Mirja L. Hämäläinen; Kalle Hoppu; Esko Valkeila; Pirkko Santavuori

Efficacy of drugs for the acute treatment of migraine in children has not so far been studied in well controlled trials.We conducted a study to evaluate the efficacy of acetaminophen and ibuprofen. Eighty-eight children, aged 4.0 to 15.8 years, with migraine participated in a double-blind crossover study. Three attacks per child were treated in random order with single oral doses of 15 mg/kg acetaminophen, 10 mg/kg ibuprofen, and placebo at home. The primary end point, reduction in severe or moderate headache (grade >or=to 3 on a scale of 1 to 5) by at least two grades after 2 hours, was reached twice as often with acetaminophen and three times as often with ibuprofen as with placebo. Ibuprofen was twice as likely as acetaminophen to abort migraine within 2 hours. In the intent-to-treat analysis, children improved twice as often with ibuprofen and acetaminophen as with placebo. Both ibuprofen and acetaminophen are effective and economical treatments for severe or moderate migraine attacks in children. Ibuprofen gave the best relief. NEUROLOGY 1997;48: 103-107


Brain & Development | 1988

Neuronal ceroid-lipofuscinoses in childhood

Pirkko Santavuori

NCL disorders are progressive brain diseases with an autosomal recessive inheritance in all eleven childhood types. These occur world-wide but may be enriched in some countries. In Finland altogether about 400 patients have been diagnosed during the last forty years. The most common types are the infantile and classic juvenile forms with an incidence of 1: 20,000 and 1: 21,000, respectively Personally followed-up are patients with infantile, classic and Finnish variant late infantile and classic juvenile types. Clinical, neurophysiological and neuroimaging findings in these four NCL forms are reviewed including also management and diagnostic aspects.


Brain & Development | 1989

Muscle-eye-brain disease (MEB)

Pirkko Santavuori; Hannu Somer; Kimmo Sainio; Juhani Rapola; Sirkka Kruus; Tuija Nikitin; Leena Ketonen; Jaakko Leisti

Clinical features of a rare congenital myopathy, muscle-eye-brain (MEB) disease, are described in 19 patients. The pedigree data suggest an autosomal recessive inheritance. The patients presented with congenital hypotonia and muscle weakness. Serum CK was elevated, EMG was myopathic and muscle biopsy showed slight or moderate changes compatible with muscular dystrophy. Ophthalmological findings included severe visual failure and uncontrolled eye movements associated with severe myopia. The flash VEPs were exceptionally high, whereas non-corneal ERG was unrecordable. The EEG showed progressive abnormalities after the age of 6 months. Psychomotor development was slow during the first years of life, and mental retardation was severe. Most patients began to deteriorate around age 5 years. This change included spasticity and joint contractures. CT scans showed ventricular dilatations and abnormally low white matter density in several patients. Spasticity, high VEPs and ocular manifestations differentiate MEB from the Fukuyama type congenital muscular dystrophy.


Journal of the Neurological Sciences | 1973

Infantile type of so-called neuronal ceroid-lipofuscinosis

Pirkko Santavuori; Matti Haltia; Juhani Rapola; Christina Raitta

A clinical description is given of a uniform series of 15 patients with a progressive encephalopathy. The disease had its clinical onset at the age of 8 to 18 months with rapid psychomotor deterioration, ataxia, and muscular hypotonia. Microcephaly and myoclonic jerks were other prominent features; convulsions were few or did not occur at all. All patients were amaurotic by the age of 2 years and had optic atrophy and macular and retinal dystrophy without pigment aggregation. Early extinction of the electroretinogram and EEG records rapidly approaching isoelectricity were additional features. The clinical picture does not fit with any previously recognized type of amaurotic idiocy. However, the diagnostic morphological and biochemical findings (see Haltia et al. 1973) have a number of features in common with the group of so-called neuronal ceroid-lipofuscinoses. The relationship of the present condition and of some previously reported similar cases to the various forms of neuronal ceroid-lipofuscinosis is discussed.


Neurology | 2001

Clinical and genetic distinction between Walker–Warburg syndrome and muscle–eye–brain disease

Bru Cormand; Helena Pihko; M. Bayes; Leena Valanne; Pirkko Santavuori; Beril Talim; Ruth Gershoni-Baruch; A. Ahmad; J.H.L.M. van Bokhoven; Han G. Brunner; T. Voit; Haluk Topaloglu; William B. Dobyns; A-E Lehesjoki

Background: Three rare autosomal recessive disorders share the combination of congenital muscular dystrophy and brain malformations including a neuronal migration defect: muscle–eye-brain disease (MEB), Walker–Warburg syndrome (WWS), and Fukuyama congenital muscular dystrophy (FCMD). In addition, ocular abnormalities are a constant feature in MEB and WWS. Lack of consistent ocular abnormalities in FCMD has allowed a clear clinical demarcation of this syndrome, whereas the phenotypic distinction between MEB and WWS has remained controversial. The MEB gene is located on chromosome 1p32-p34. Objectives: To establish distinguishing diagnostic criteria for MEB and WWS and to determine whether MEB and WWS are allelic disorders. Methods: The authors undertook clinical characterization followed by linkage analysis in 19 MEB/WWS families with 29 affected individuals. With use of clinical diagnostic criteria based on Finnish patients with MEB, each patient was categorized as having either MEB or WWS. A linkage and haplotype analysis using 10 markers spanning the MEB locus was performed on the entire family resource. Results: Patients in 11 families were classified as having MEB and in 8 families as WWS. Strong evidence in favor of genetic heterogeneity was obtained in the 19 families. There was evidence for linkage to 1p32-p34 in all but 1 of the 11 pedigrees segregating the MEB phenotype. In contrast, linkage to the MEB locus was excluded in seven of eight of the WWS families. Conclusion: These results allow the classification of MEB and WWS as distinct disorders on both clinical and genetic grounds and provide a basis for the mapping of the WWS gene(s).


Neurology | 1997

Sumatriptan for migraine attacks in children: A randomized placebo‐controlled study Do children with migraine respond to oral sumatriptan differently from adults?

Mirja L. Hämäläinen; Kalle Hoppu; Pirkko Santavuori

Oral sumatriptan is an effective acute treatment for migraine in adults, but its efficacy in children is still undetermined. Twenty-three children, aged 8.3 to 16.4 years, took both sumatriptan and placebo in a randomized, double-blind, placebo-controlled, crossover trial. The primary endpoint was a ≥50% decrease in pain intensity on a 100-mm visual analogue scale at 2 hours. Other endpoints of efficacy were pain intensity difference (PID), showing pain relief at each time point; summed pain intensity differences (SPIDs), estimating overall pain relief; and preference. Two hours after sumatriptan, 7 of 23 reached the primary endpoint, and after placebo, 5 of 23 (difference 9%, 95% CI for difference, −21 to 38%; p = ns). Within 2 hours, the headache disappeared completely in 5 of 23 children after sumatriptan and in 2 of 23 children after placebo (p = ns). Median PIDs were slightly better for sumatriptan between 0.5 and 4 hours (p = ns). Median SPIDs increased almost identically up to 2 hours. Thereafter, median SPIDs for placebo remained practically constant, whereas for sumatriptan, the improvement continued. At 4 hours, the median SPID for sumatriptan was 2.4 times as high as for placebo. However, the maximum differences between median SPIDs at 4 hours (38.5, 95% CI, −75.8 to 57.5; Wilcoxon signed rank test, p = 0.4) or at any other point were not statistically significant. Of the 23 children, 13 preferred sumatriptan and 2 placebo (sign test, p = 0.004). The failure of this and previous controlled studies suggests that the response of children to sumatriptan may be different from adults.


American Journal of Human Genetics | 1999

Assignment of the muscle-eye-brain disease gene to 1p32-p34 by linkage analysis and homozygosity mapping.

Bru Cormand; Kristiina Avela; Helena Pihko; Pirkko Santavuori; Beril Talim; Haluk Topaloglu; Albert de la Chapelle; Anna-Elina Lehesjoki

Muscle-eye-brain disease (MEB) is an autosomal recessive disease of unknown etiology characterized by severe mental retardation, ocular abnormalities, congenital muscular dystrophy, and a polymicrogyria-pachygyria-type neuronal migration disorder of the brain. A similar combination of muscle and brain involvement is also seen in Walker-Warburg syndrome (WWS) and Fukuyama congenital muscular dystrophy (FCMD). Whereas the gene underlying FCMD has been mapped and cloned, the genetic location of the WWS gene is still unknown. Here we report the assignment of the MEB gene to chromosome 1p32-p34 by linkage analysis and homozygosity mapping in eight families with 12 affected individuals. After a genomewide search for linkage in four affected sib pairs had pinpointed the assignment to 1p, the MEB locus was more precisely assigned to a 9-cM interval flanked by markers D1S200 proximally and D1S211 distally. Multipoint linkage analysis gave a maximum LOD score of 6.17 at locus D1S2677. These findings provide a starting point for the positional cloning of the disease gene, which may play an important role in muscle function and brain development. It also provides an opportunity to test other congenital muscular dystrophy phenotypes, in particular WWS, for linkage to the same locus.


Journal of the Neurological Sciences | 1973

Infantile type of so-called neuronal ceroid-lipofuscinosis ☆: Part 2. Morphological and biochemical studies

Matti Haltia; Juhani Rapola; Pirkko Santavuori; Antti Keränen

Morphological and biochemical data are given on brain biopsy or autopsy samples from 13 patients with a progressive encephalopathy, characterized clinically by the onset of rapid psychomotor deterioration at about 1 year of age, early amaurosis, and absence or relative paucity of convulsions. The main morphological feature was very severe neuronal destruction, accompanied by a massive occurrence of frequently binucleated phagocytes and unusually hypertrophic fibrillary astrocytes in the cerebral cortex. The remaining neurons and glial cells contained excessive amounts of autofluorescent granules with the staining properties of lipofuscin, and with strong acid phosphatase activity. The homogeneous granular ultrastructure of the storage material differed both from ordinary neuronal lipofuscin and from the storage material in most previous reports on so-called neuronal ceroid-lipofuscinosis. Biochemically the biopsy samples were characterized by a decrease in lipid-bound N-acetylneuraminic acid. Thus, the unusual but uniform clinical, morphological and biochemical findings in our series of 13 patients differ from the findings in previously recognized types of amaurotic idiocy. These 13 patients—and possibly some others collected from the literature—appear to constitute a clearly separable group; the relationship of this condition to various forms of neuronal ceroid-lipofuscinosis is discussed.


Genomics | 1991

Infantile form of neuronal ceroid lipofuscinosis (CLN1) maps to the short arm of chromosome 1

Irma Järvelä; Johanna Schleutker; Leena Haataja; Pirkko Santavuori; Lea Puhakka; Tuula Manninen; Aarno Palotie; Lodewijk A. Sandkuijl; Martin Renlund; R. White; Pertti Aula; Leena Peltonen

The neuronal ceroid lipofuscinoses (CLNs) are one of the most common progressive encephalopathies of childhood in Western countries. They are divided into three main types: infantile, late infantile, and juvenile. The inheritance of all forms is autosomal recessive, and the biochemical background is totally unknown. The infantile type (CLN1) demonstrates the earliest onset of symptoms and the most severe clinical course. CLN1 is enriched in the Finnish population with incidence of 1:20,000, and only about 50 cases have been reported from other parts of the world. We have collected 15 Finnish CLN1 families with one or two diseased children for a linkage analysis with polymorphic probes randomly localized on human chromosomes. After studying 42 polymorphic protein and DNA markers, we found definitive proof of linkage with three different probes on the short arm of chromosome 1, with maximum lod scores of 3.38 at theta = 0.00 (0.00-0.08) for D1S57 (pYNZ2), 3.56 at theta = 0.00 (0.00-0.09) for D1S7 (lambda MS1), and 3.56 at theta = 0.00 (0.00-0.11) for D1S79 (pCMM8). With the assignment of the CLN1 gene, our study demonstrates the power of multiallelic VNTR probes in the search for linkage of a rare recessive disorder using limited family material.

Collaboration


Dive into the Pirkko Santavuori's collaboration.

Top Co-Authors

Avatar

Taina Autti

University of Helsinki

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Matti Haltia

Helsinki University Central Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Helena Pihko

Helsinki University Central Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge